Source of business for biosimilars in immunology
As of August 2023, there were 40 FDA-approved biosimilar products, including 25 commercially available products and four with interchangeable status.1 Adoption...
Brendan Kelly
Vice President
Dr. Brendan Kelly is a vice president in the Life Sciences Practice of CRA. He has extensive client and project management experience and expertise developing and leading projects that answer client’s data-driven business questions. Dr. Kelly has worked on strategic and analytics-driven consulting projects involving rare disease products, autoimmune diseases, CNS diseases, and biosimilar portfolios. Prior to his role at CRA, he was a Director at C1 Consulting.
Credentials
Get In Touch
Brendan Kelly